- Home
- AZZ vs DNLI Comparison
AZZ vs DNLI Comparison
Compare AZZ & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZZ | DNLI |
|---|---|---|
| Founded | 1956 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | AZZ | DNLI |
|---|---|---|
| Price | $109.09 | $16.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $116.33 | $32.58 |
| AVG Volume (30 Days) | 193.5K | ★ 1.8M |
| Earning Date | 01-07-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | ★ 855.67 | N/A |
| EPS | ★ 10.37 | N/A |
| Revenue | ★ $1,594,766,000.00 | N/A |
| Revenue This Year | $5.21 | N/A |
| Revenue Next Year | $5.18 | $3,993.60 |
| P/E Ratio | $10.45 | ★ N/A |
| Revenue Growth | ★ 1.55 | N/A |
| 52 Week Low | $70.90 | $10.57 |
| 52 Week High | $119.95 | $24.35 |
Technical Indicators
Market Signals| Indicator | AZZ | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 58.94 | 43.71 |
| Support Level | $106.66 | $16.66 |
| Resistance Level | $111.13 | $18.30 |
| Average True Range (ATR) | 2.82 | 1.01 |
| MACD | 0.24 | -0.36 |
| Stochastic Oscillator | 65.96 | 5.57 |
Price Performance
Historical ComparisonAbout AZZ AZZ Inc.
AZZ Inc is a provider of galvanizing and a variety of metal coating solutions and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of Metal Coatings, Precoat Metals, and Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company generates the majority of its revenue from the United States.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.